Click on a filter below to refine your search. Remove a filter to broaden your search.
For every starting age between 50 and 80 years, the projected mean event-free survival was numerically greater with finerenone versus placebo.
The greatest incidence was seen for metastatic, hematological and lung cancer; an increased risk for CVD was seen with chemotherapy.
A lower diligence level was linked to the risk for new cardiovascular disease, but a healthy lifestyle still was beneficial.
In 2019 to 2020, 56% of patients with high cholesterol were on statins for primary prevention and 85% were on them for secondary prevention.
The benefits of chronologically timed light therapy now extend to lowering the risk for heart disease, a new study shows.
Lower risks for first heart failure hospitalization and total heart failure hospitalization were seen with empagliflozin.
A reduced risk was seen for venous thromboembolism, arterial thrombosis/thromboembolism and heart failure.
24.9 percent received creatinine and UACR screening; Hispanic ethnicity associated with lack of screening
The findings were seen for residents of remote areas and small towns compared with those living in cities.
The findings were seen for overall accelerometer-measured physical activity and light or moderate-to-vigorous activity, as well as for steps per day.